The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms deep vein thrombosis and acute coronary syndrome with said dosage form.

The invention encompasses pharmaceutical compositions and methods for using Compound (1) in combination with other agents for treating patients with AIDS of HIV infection.

Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition such as for example inflammatory disease and pharmaceutical compositions comprising such compounds.

The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer an SGLT2 inhibitor formulation as the second layer and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition such as for example inflammatory disease and pharmaceutical compositions comprising such compounds.

This invention provides compounds having drug and bio-affecting properties their pharmaceutical compositions and method of use. In particular the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity whether used alone or in combination with other antivirals antiinfectives immunomodulators or HIV entry inhibitors. More particularly the present invention relates to the treatment of HIV and AIDS.

The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents the one or more organic solvents together being an antisolvent for the active pharma...

In the present invention there is described the use of metformin and glyburide for the preparation of a pharmaceutical composition containing a low dose combination of metformin and glyburide wherein said pharmaceutical composition is intended for the treatment of type 2 diabetes in a drug naive human patient where the combination of metformin and glyburide comprising 250 mg metformin and 1.25 mg glyburide is intended for administration and has a given distribution of glyburide particle size. A ...

Disclosed are compressed tablets containing atazanavir sulfate optionally with another active agents e.g. anti-HIV agents granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets compositions comprising a plurality of the granules processes for making the granules and tablets and methods of treating HIV.

The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer an SGLT2 inhibitor formulation as the second layer and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.